Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

John Theurer Cancer Center at Hackensack University Medical Center: Providing Extraordinary Care to the Community

February 14th 2012

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

Dr. Ramaswamy on Dormant Tumor Cells and Resistance

February 13th 2012

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Baselga on the Basis Behind the BOLERO-2 Trial

February 7th 2012

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Cohen on mTOR Inhibition in Head and Neck Cancer

February 3rd 2012

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Dr. Ramaswamy on Targeting Dormant Cancer Cells

February 1st 2012

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells

Dr. Burris Discusses Targeting the mTOR Pathway

January 31st 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Cohen Addresses the Role of the Hedgehog Pathway

January 30th 2012

Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway

Dr. Bloom Compares HER2 Screening Assays

January 30th 2012

Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays

Noted Researcher Sees ERT as Remarkable Beginning

January 26th 2012

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Dr. Berenson Discusses Early Phase Proteasome Inhibitors

January 24th 2012

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

Changing Paradigms for NSCLC in Personalized Therapy Era

January 20th 2012

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Dr. Burstein on Pathological Complete Response

January 20th 2012

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

PARP Inhibition Explored in Triple-Negative Breast Cancer

January 16th 2012

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Dr. Chan Discusses the VEGF-Trap Agent Aflibercept

January 13th 2012

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

Dr. Cohen Discusses Hedgehog Pathway Inhibition

January 13th 2012

Dr. Deirdre Cohen, NYU Medical Oncology Associates, Discusses Hedgehog Pathway Inhibition

DNA Analysis Finds First Gene Implicated in Prostate Cancer

January 12th 2012

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

From Warfare to Mainstay: Mustard Derivatives Play Evolving Role in Cancer Therapy

January 9th 2012

Mustard derivatives' potent lethality has ensured its descendents a place in oncology treatment regimens today, even amid advances in targeted therapies.

5 Questions on the Development of p53

December 22nd 2011

p53 coordinates a number of antiproliferative programs in response to multiple forms of stress, including low oxygen, depletion of ribonucleotides, hyperactivation of growth signaling, and many forms of DNA damage.